A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia
Clinical trial NCT06024876 · COMPLETED
Trial details
- NCT number
- NCT06024876
- Sponsor
- CorrectSequence Therapeutics Co., Ltd
- Status
- COMPLETED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-26
- Primary completion
- 2025-07-01
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.